Kertes, 5,124 patient tixagevimab/cilgavimab prophylaxis study: 92% lower combined mortality/hospitalization [p=0.01] and 47% fewer cases [p=0.01] https://c19p.org/kertes
copied to clipboard
Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac625
Retrospective 825 immunocompromised individuals treated with tixagevimab-cilgavimab and 4229 untreated in Israel, showing significantly lower infection and hospitalization/death with treatment. Omicron was the dominant variant.Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2 [Zhou].
|
risk of death/hospitalization, 91.9% lower, RR 0.08, p = 0.01, treatment 1 of 825 (0.1%), control 63 of 4,299 (1.5%), NNT 74, adjusted per study, odds ratio converted to relative risk, multivariable.
|
|
risk of case, 47.1% lower, RR 0.53, p = 0.01, treatment 29 of 825 (3.5%), control 308 of 4,299 (7.2%), NNT 27, adjusted per study, odds ratio converted to relative risk, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Kertes et al., 7/29/2022, retrospective, Israel, peer-reviewed, 10 authors.
Contact:
dortal_j@mac.org.il, zeny@013.net.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.